Global Anticoagulants Market to Spike to Over $24 Billion by 2019
This newly published “New Oral Anticoagulants Markets” report that the global anticoagulants market will spike to over $24 billion by 2019.
Anticoagulants can be categorized into five main modalities: low molecular weight heparins (LMWHs), herapins, warfarin, direct thrombin inhibitors (DTIs) and factor Xa inhibitors. The U.S. anticoagulants market, which encompasses over 60% of the global market for anticoagulants, will grow from $7.06 billion in 2012 to $15.32 billion in 2019 as it shifts from being monopolized by a single injectable anticoagulant, warfarin, to once-daily oral anticoagulants.
The “New Oral Anticoagulants Markets” report covers:
- Dabigatran (Pradaxa)
- Rivaroxaban (Xarelto)
- Eliquis (Apixaban)
- Edoxaban
- Betrixaban
- Antiplatelets
- Clotting Assays
- Cardiovascular Diseases
- Cardiac Arrhythmia
- Coronary Artery Disease
- Myocardial Infarction
- Heart Valve Replacement
- Deep Vein Thrombosis (DVT)
The “New Oral Anticoagulants Markets” report examines companies manufacturing anticoagulant equipment and supplies in the world.
Companies covered include:
- Akers,
- Anthera,
- ARYx,
- AstraZeneca,
- Boehringer Ingelheim,
- Cipla,
- Daiichi Sankyo,
- Eisai,
- Eli Lilly,
- Genentech,
- GlaxoSmithKline,
- Medicines Company,
- Medicure,
- Merck,
- Novartis,
- Ortho-McNeil,
- Pfizer,
- Pharmion,
- Portola and Sanofi.